...
首页> 外文期刊>Implant dentistry >CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
【24h】

CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.

机译:CTX骨代谢的生化标志物。手术后双膦酸盐相关的颌骨坏死是否可靠的预测指标?第二部分:前瞻性临床研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Biochemical markers of bone metabolism have been used in medicine to evaluate and provide treatment to patients with metabolic bone diseases, such as osteoporosis. Serum cross-linked C-telopeptide of type I collagen (CTX) is a marker of osteoclast activity and is used to assess the level of bone resorption. Recently, in oral and maxillofacial surgery, it was proposed that the levels of serum CTX may predict the subsequent risk of developing osteonecrosis of the jaws (ONJ) after oral surgery procedures for patients taking oral bisphosphonates (BPs). The goal of this study was to determine whether this specific serum marker of bone resorption could preoperatively predict the risk of developing ONJ from oral BPs.We hypothesized that there is no clinical correlation between the observed preoperative serum CTX values and the risk of developing ONJ. The authors examine the scientific basis (validity) of the morning fasting serum CTX test in 163 consecutive patients who underwent various oral surgery procedures in the office. The authors also review the laboratory test results and the recommended protocol based on the test values. One hundred sixty-three patients (mean age, 75.9 years) were divided into 2 groups. Group I was the control group that consisted of 109 patients taking oral BPs who did not take the CTX test preoperatively. Group 2 consisted of 54 patients taking BPs and who elected to have the CTX test performed to assess their level of risk of developing ONJ, preoperatively. Both groups of patients were observed for a period of 8 weeks for signs and symptoms of BP-associated ONJ after surgery. The clinical data at 8 weeks and beyond revealed that there was no evidence of BP-associated ONJ in all participants. We conclude that the serum CTX is not a valid preoperative test to accurately assess the level of risk of developing ONJ and is not indicated in the oral surgery patient.
机译:骨代谢的生化标志物已用于医学中,以评估代谢性骨疾病(例如骨质疏松症)并为患者提供治疗。 I型胶原蛋白的血清交联的C-端肽(CTX)是破骨细胞活性的标志物,用于评估骨吸收水平。最近,在口腔和颌面外科手术中,有人提出口服双膦酸盐(BP)的患者在进行外科手术后,血清CTX的水平可以预测随后发生颌骨坏死(ONJ)的风险。这项研究的目的是确定这种特定的骨吸收血清标志物能否在术前预测口服BP导致ONJ的风险。我们假设观察到的术前血清CTX值与发生ONJ的风险之间没有临床相关性。作者检查了连续163名在办公室进行了各种口腔手术的患者的早晨空腹血清CTX测试的科学依据(有效性)。作者还回顾了实验室测试结果以及基于测试值的推荐方案。 163例患者(平均年龄75.9岁)分为两组。第一组是对照组,由109名接受口服BP的患者组成,这些患者术前未进行CTX测试。第2组由54位服用BP的患者组成,他们选择术前进行CTX测试以评估其发展为ONJ的风险水平。观察两组患者术后8周与BP相关的ONJ的体征和症状。 8周及以后的临床数据显示,所有参与者均没有证据表明与BP相关的ONJ。我们得出的结论是,血清CTX并不是有效的术前测试,不能准确评估发展为ONJ的风险水平,并且没有在口腔外科手术患者中使用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号